VXRT250117P2000
- 1.44
- 0.000.00%
Vaxart Newsroom
Vaxart Project Agreement Change Ups Funding for Oral COVID Vaccine Candidate
Sector Update: Health Care Stocks Lower in Late Afternoon Trading
Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study
Express News | Vaxart - Funding Ceiling Increased to About $460.7 Million; Funding for Trial Increased to About $134.2 Million
Express News | Vaxart Inc - Enters Into Modification No. 4 to Project Agreement With Advanced Technology International
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Vaxart Completes Enrollment Of The Sentinel Cohort In Its Phase 2b Study Of Its COVID-19 Oral Pill Vaccine Candidate
Express News | Vaxart Completes Enrollment of Sentinel Cohort in Phase 2B Study Evaluating Its Covid-19 Oral Pill Vaccine Candidate
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
Express News | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
Vaxart's Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy Rating
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4
Vaxart (VXRT) Receives a Buy From Oppenheimer
Vaxart's Q3 2024: Progress in Oral Vaccine Development